Biosimilar Dealmaking Moves The Needle Forward
Executive Summary
Dealmaking is advancing the biosimilar field. Since 2000, the volume of biosimilar deals has grown at a 15% compound annual rate.
You may also be interested in...
Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals
Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.
Shire Exits Biosimilars, Streamlines Oncology Business
Terminating a pair of biosimilar partnerships inherited from Baxalta will better enable Shire to focus on core strengths, CEO Ornskov says. The firm will use Baxalta assets to gradually develop a cancer franchise.
Teva’s 'Key Ingredient' For Growth: Biosimilars
Teva has conducted due diligence on 36 biosimilar companies with the aim of signing a partner soon to fill a critical gap in its generics pipeline.